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Maintenance of multipotency and how cells exit this
state to adopt a specific fate are central questions
in stem cell biology. During vertebrate development,
multipotent cells of the dorsal somite, the dermo-
myotome, give rise to different lineages such as
vascular smooth and skeletal muscle, regulated by
the transcription factors Foxc2 and Pax3, respec-
tively. Here we show reciprocal inhibition between
Pax3 and Foxc2 in the mouse embryo. Using both
genetic approaches and manipulation of external
signals in somite explants, we demonstrate that the
Pax3:Foxc2 ratio modulates myogenic versus vas-
cular cell fates. This provides insight into how cell
fate choices are orchestrated by these lineage genes
in the dermomyotome.INTRODUCTION
Pax genes play key roles during tissue specification (Bucking-
ham and Relaix, 2007). The formation and growth of skeletal
muscle depends on the transcription factors Pax3 and Pax7.
Myogenic progenitor cells derive from the dorsal somite, the der-
momyotome, which also gives rise to derm, to endothelial and
smooth muscle cells of blood vessels, and also to a subpopula-
tion of brown fat cells (Buckingham and Vincent, 2009). Labeling
experiments in the chick embryo have shown that a single cell
can give rise to different cell types (Kardon et al., 2002; Ben-
Yair and Kalcheim 2005, 2008). In the mouse, retrospective
clonal analysis demonstrates a common progenitor for the skel-
etal muscle of the myotome and the smooth muscle of the
dorsal aorta, and genetic lineage studies confirm that the Pax3-
positive cells of the dermomyotome contribute to the wall of the
blood vessel (Esner et al., 2006). Such cells cease to express
Pax3 as they delaminate from the dermomyotome epithelium,892 Developmental Cell 17, 892–899, December 15, 2009 ª2009 Elswhereas cells that migrate from this structure to form limb
muscles, for example, maintain Pax3 expression. A major source
of muscle progenitor cells derives from the central domain of the
dermomyotome where Pax3 and Pax7 are both expressed
(Buckingham and Relaix 2007). Pax3/7 ensure cell survival and
control myogenic potential through the activation of myogenic
determination genes such as Myf5 or MyoD (Relaix et al.,
2005; Bajard et al., 2006; Hu et al., 2008). However, it is not clear
how multipotency is maintained in the dermomyotome. Nor is it
clear how cell fate choices in response to external signals are
modulated, with retention of Pax3 expression in myogenic
progenitor cells or downregulation of these genes prior to entry
into an alternative lineage.
We now identify Foxc2 as a gene that is negatively regulated
by Pax3 and show reciprocal negative regulation of Pax3 by
Foxc2. Foxc2 is coexpressed with Pax3 in the somite and is
subsequently expressed in the dorsal aorta. This transcription
factor has been shown to play a role in tissue regulation at
different sites in the embryo, including blood vessels where it
is expressed in smooth muscle and endothelial cells (De Val
et al., 2008; Kume 2008). Compound mutant analyses and
manipulation of somite explants indicate that the Pax3/Foxc2
ratio affects myogenic versus vascular cell fate choices, leading
us to propose that modulation of the equilibrium between Pax3
and Foxc2 expression in multipotent cells of the somite regulates
entry into a specific lineage.RESULTS
Foxc2 Is Negatively Regulated by Pax3
In order to identify Pax3 targets at the onset of myogenesis, cells
purified by flow cytometry from Pax3GFP/+ heterozygote and
Pax3GFP/PAX3-FKHR gain of function (Relaix et al., 2003) embryos
were used for comparative transcriptome analysis (unpublished
data). Foxc2 was identified as a gene negatively regulated by
Pax3 (3.16-fold). Foxc2 is initially expressed with Pax3 in the
epithelial somite (Figures 1A and 1C). Subsequently, whenevier Inc.
Figure 1. Genetic Analysis Shows Reciprocal
Repression between Foxc2 and Pax3
(A–D) Transverse sections of embryonic day (E) 10.5
embryos in the caudal region after whole-mount in situ
hybridization show Pax3 (A) and (B), or Foxc2 (C and D)
transcripts in an immature epithelial somite (So 2–3, where
the most newly formed somite [So] is 1) (A and C) and
a more mature somite (So 6–7) (B and D).
(E–G) Single cell qPCR analysis on Pax3-GFP-positive
cells separated by flow cytometry from epithelial caudal
(So 2-4) or more mature (So13-20) interlimb somites from
an E10.5 Pax3GFP/+ embryo, shown as a whole mount,
under a fluorescent microscope. The somites used for
dissection are outlined (E). Examples of amplification plots
are shown for a single cell isolated from an interlimb somite,
with DRn (normalized fluorescence from amplifying target)
on the yaxis and the number of amplification cycles on the x
axis. The negative control is without cDNA (F). Results for
Foxc2, Pax3, and Pax7 transcripts are summarized in (G).
n, number of cells showing coexpression compared to
the total number of cells with Pax3 transcripts.
(H–M) Whole-mount in situ hybridization showing Foxc2
transcripts on control (wild-type [WT] or heterozygote
Pax3GFP/+) (H, J, and L), Pax3PAX3-FKHR/+ gain-of-function
(I), Pax3GFP/GFP loss-of-function (K), and Pax3Pax3-En/+
partial loss-of-function (M) embryos at E10.5 (H and I) or
E9.5 (J–M). (L0 and M0) Transverse sections of (L) and (M)
at the level indicated by the white bar (So 5). DA, dorsal
aorta; DM, dermomyotome; NT, neural tube. Yellow arrows
point to the dermomyotyome (B and D) or to differences
between control and mutant embryos (H–M0). Scale bar,
50 mm (A–D).
(N and O) Quantitative PCR of the relative levels of Pax3 (N)
and Pax7 (O) compared to Gapdh transcripts for the inter-
limb region of Foxc2/ or control (Foxc2+/+ and Foxc2+/)
embryos. Histograms represent mean fold change for
four different biological samples analyzed in duplicate at
each stage; error bars, standard error to the mean (SEM);
*p < 0.05.
(P and Q) Whole-mount in situ hybridization for Pax7
transcripts on control (P) and Foxc2/ (Q) embryos at
E10.75 in the interlimb region (dotted lines outline a somite).
(R and S) Immunohistochemistry with a Pax7 antibody on
transverse sections, showing the hypaxial lip (Hyp lip) of
the dermomyotome of an interlimb somite at E11. Scale
bar, 50 mm (R and S).
Developmental Cell
Pax3 and Foxc2 Genetic Interactions in the SomitePax3 transcripts become confined to the dorsal dermomyotome
(Figure 1B), Foxc2 transcripts are high in the ventral sclerotome
and lower in the dermomyotome (Figure 1D), where they notably
still accumulate in the hypaxial domain. In order to confirm that
Pax3 and Foxc2 are expressed in the same cells, qPCR was per-
formed on single Pax3-GFP-positive cells isolated by flow
cytometry from epithelial or more mature somites of Pax3GFP/+
embryos (Figure 1E) using the procedure as described in Peixoto
et al., 2004. We could demonstrate coexpression of Pax3 and
Foxc2 transcripts in the same cell (Figures 1F and 1G), both
from immature epithelial somites and from more mature somites.
In the latter, some cells also coexpress Pax7. As expected from
the screen, Foxc2 is downregulated in Pax3PAX3-FKHR/+ gain-of-
function embryos (Figure 1I). Conversely, Foxc2 expression is up-
regulated in Pax3 null embryos (Figure 1K) and in Pax3Pax3-En/+
embryos that show partial loss of Pax3 function (Bajard et al.,
2006) (Figure 1M). In the latter, Foxc2 transcripts are increased
in the dermomyotome (Figure 1M0).DevelopmePax3 and Pax7 Are Negatively Regulated by Foxc2
Analysis of Foxc2 mutants shows that, reciprocally, in the
absence of Foxc2, Pax3 is upregulated (Figure 1N). This is diffi-
cult to appreciate by in situ hybridization, since Pax3 is highly
expressed throughout the dermomyotome (Figure 1B). However
Pax7 expression, seen in more mature somites where it is nor-
mally concentrated in the central dermomyotome domain (Buck-
ingham and Relaix 2007), is also upregulated in the absence of
Foxc2 (Figure 1O), and Pax7 transcripts are now present at a
much higher level in cells in the hypaxial domain (Figures 1P and
1Q). This is also seen at the protein level (Figures 1R and 1S).
These results therefore suggest reciprocal repression between
Pax3/7 and Foxc2 in the multipotent cells of the dermomyotome.
Genetic Interactions between Foxc2 and Pax3
Since Foxc2 expression is upregulated in Pax3 mutants, we
next asked whether removal of Foxc2 affects these
phenotypes by examining compound mutants. In Pax3Pax3-En/+ntal Cell 17, 892–899, December 15, 2009 ª2009 Elsevier Inc. 893
Figure 2. Foxc2 Removal Rescues Aspects of Pax3 Mutant Pheno-
types
(A–C) Whole-mount X-Gal staining of control Pax3nlacZ/+ (A);
Pax3Pax3-En-IRESnlacZ/+; Foxc2+/ (P3Pax3-En/+; C2+/) (B); and P3Pax3-En/+; C2/
(C) embryos.
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894 Developmental Cell 17, 892–899, December 15, 2009 ª2009 Els(Pax3Pax3-En-IRESnlacZ/+) embryos, Pax3-expressing cells, marked
by b-galactosidase, are maintained but do not migrate to the
forelimb, and myogenesis in the hindlimb is curtailed (Figures
2B and 2E). In the absence of Foxc2, myogenic cells, marked
by MyoD expression, are now present in the forelimb
(Figure 2F0), and their contribution to the hindlimb (Figure 2F00)
is increased (Figures 2C and 2F). Expression of c-met, which is
a Pax3 target required for dermomyotomal delamination and
subsequent migration of cells to the limb buds (Birchmeier and
Brohmann 2000; Buckingham and Relaix 2007), is upregulated
(Figure 2I), consistent with the removal of Foxc2 repression of
Pax3. A similar phenotype is also seen in Pax3PAX3-FKHR/+ gain-
of-function embryos (Relaix et al., 2003). In Pax3 mutants, as
the somite matures, there is extensive cell death leading to a
reduction in the hypaxial dermomyotome (Figures 2K and 2N).
In Pax3/; Foxc2/ double mutants, the hypaxial dermomyo-
tome is more extensive (Figure 2O) and retains more epithelial
structure, as indicated by the expression of ZO-1 that marks tight
junctions of epithelial cells (Bultje et al., 2009) (see Figure S1
available online). Upregulation of Pax7 (Figures 1O–1S), also
seen in the double mutants (data not shown), probably explains
the reduction in apoptosis in the absence of Foxc2 (Figure 2P).
Proliferation is also notably increased in the dermomyotome of
the double mutants (Figure 2Q). This is also seen in the absence
of Foxc2 on a wild-type Pax3 background (Figure 2R), demon-
strating the Pax3/7 gain-of-function effect, despite a potential
proproliferative, antiapoptotic effect of Foxc2, reported for the
ventral somite (Winnier et al., 1997). The upregulation of Pax7
in the absence of Foxc2, also has functional consequences for
limb myogenesis. In Pax3+/; Foxc2/ embryos, there are fewer
Pax3-positive myogenic cells in the developing forelimbs(D–I) Whole-mount in situ hybridization for MyoD (D–F00) and c-met (G–I) tran-
scripts in wild-type controls (D and G), P3Pax3-En/+; C2+/ (E and H), and
P3Pax3-En/+; C2/ embryos (F and I). (D0–F0) and (D00–F00) represent an enlarged
view of the fore- and hindlimb bud, respectively, of the embryos shown in
(D)–(F). Red arrows point to differences in limb (B, C, E, F) or interlimb somite
(H and I) expression.
(J–L) Interlimb view of embryos after X-Gal staining: Pax3nlacZ/+; Foxc2+/
(P3nlacZ/+;C2+/) control double heterozygote (J), P3nlacZ/nlacZ; C2+/
compound mutant (K), and P3nlacZ/nlacZ; C2/ double mutant (L) embryos.
Red arrows indicate the hypaxial region extending beyond the yellow bar
that marks the total extent of somite staining in (L).
(M–O) Coimmunohistochemistry on control (M), compound (N), and double
mutant (O) embryos as in (J) – (L) at E10.5 (somite stage 35), at an equivalent
interlimb level, stained with antibodies to b-galactosidase (ßGal) and to skel-
etal muscle myosin heavy chain MF20. In (O), the white arrow indicates the
hypaxial lip and the boxed area ectopic myogenic cells close to the dorsal
aorta. NT, neural tube.
(P–R) Quantification of apoptosis (P) and proliferation (Q and R) in interlimb
somites after immunostaining on sections using antibodies to Activated Cas-
pase3 (Casp3Act) (P) or Phospho-histone H3 (PHH3) (Q and R), which mark
apoptotic and proliferating cells, respectively. Casp3A (P) or PHH3 (Q) positive
cells that were also b-galactosidase postive (P3/, Pax3nlacZ/nlacZ) are
expressed as a percentage of the total number of b-galactosidase positive
cells per section. In (R), PHH3-positive, Pax3-positive cells are expressed as
a percentage of the total number of cells labeled with a Pax3 antibody per
section. Pax3-positive cells in the dermomyotome were counted (number of
embryos [n], n = 3 for P3/; C2+/, n = 2 for P3/; C2/; n = 4 for C2+/,
n = 3 for C2/). A minimum of 10 sections and 50 ßGal or Pax3-positive cells
per section were examined for each genotype. Error bars, SEM; *p < 0.05;
**p < 0.005. Scale bar, 50 mm in (M)–(O).
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Figure 3. Analysis of Dermomyotomal Cell Fates in Foxc2 Mutants
(A–D) Whole-mount in situ hybridization showing an interlimb view of wild-type
(C2+/+) (A and C) and Foxc2/ (C2/) embryos (B and D) using probes for
Lbx1 at E9 (A and B) or MyoD at E11.5 (C and D). Yellow arrowheads point
to Lbx1 expression and yellow arrows point to the intersomitic region where
MyoD-positive cells are mislocated in the absence of Foxc2.
(E) Quantification of transcripts by qPCR for myogenic markers, Myogenin,
Desmin (not expressed at an appreciable level in the dorsal aorta at this stage),
and TroponinT1 relative to Gapdh levels in trunk extracts of E11.5 control
(Foxc2+/+, Foxc2+/) and Foxc2/ embryos.
(F–K) Immunohistochemistry on sections of wild-type Foxc2+/+ (C2+/+) (F),
Foxc2/ (C2/) (G), Pax3nlacZ/+; Foxc2+/ (P3+/; C2+/) (H), Pax3nlacZ/+
(P3nlacZ/+) (J), and Pax3nlacZ/+; Foxc2/ (P3+/;C2/) (I and K) embryos, using
an antibody to Pax7 (F and G) or b-galactosidase (ßGal) (H–I) or b-galactosi-
dase (ßGal) and smooth muscle actin (a-SMA) (J–K). (L) Quantification by
qPCR of transcripts for smooth muscle myosin heavy chain isoform 11
(Myh11) and an endothelial marker, angiopoietin2 (Ang2), in trunk extracts of
Foxc2/ or Pax3nlacZ/GFP (Pax3/) embryos at E10.5; mRNA levels are rela-
tive to Gapdh transcripts with the control level taken as 1. Histograms repre-
sent mean fold change of three biological samples analyzed in duplicates for
each genotype; error bars, SEM; *p < 0.05. DA, dorsal aorta. Scale bar,
50 mm in (F)–(K).
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a reduction of skeletal muscles (Figures S2A–S2J). This is prob-
ably due to the upregulation of Pax7 in the Foxc2mutant (Figures
1O–1S; Figures S2K–S2I). We had previously shown that
abnormal premature expression of Pax7 in Pax3Pax7/+ mice has
a negative effect on limb myogenesis (Relaix et al., 2004).
Regulation of Cell Fate in the Dermomyotome
The absence of Foxc2 in the somite, with consequent upregula-
tion of Pax3/7, does not only compensate Pax3 loss-of-function
phenotypes, but also promotes the myogenic cell fate in cells
that do not normally contribute to muscle, as seen in Figure 2O
where b-galactosidase-positive (Pax3nlacZ) cells that are also
expressing skeletal muscle myosin are now found ventrally
(boxed area). The domain of Lbx1 expression which marks cells
in the hypaxial dermomyotome that will contribute to migratory
myogenic cells (Birchmeier and Brohmann 2000) is expanded
in the Foxc2 mutant (Figure 3B) (Wilm et al., 2004). Reported
early downregulation of Myf5 activation in the epaxial dermo-
myotome, which does not depend directly on Pax3, may be
related to perturbations in early patterning (Wilm et al., 2004).
However, at later stages, there is an excess of MyoD-positive
cells that are no longer restricted to the muscle mass of the
myotome (Figure 3D and data not shown), as also seen in the
Pax3PAX3-FKHR/+ gain-of-function phenotype (Relaix et al.,
2003), leading to an increase in differentiated skeletal muscle
markers (Figure 3E). We conclude that removal of Foxc2 pro-
motes skeletal myogenesis. This effect originates in the multipo-
tent cells of the dermomyotome where Foxc2 is expressed
(Figure 1); proliferation and entry into the skeletal muscle pro-
gram of the myogenic Pax3-positive progenitor cell population
is not affected, as shown for the myotome (Figure S3).
Cells that delaminate ventrally from the dermomyotome and
migrate toward the dorsal aorta, before integrating into the wall
of thisblood vessel (Esner et al., 2006), normally no longer express
Pax3/7. However, in the absence of Foxc2, they continue to
express these genes, as shown for Pax7 (Figure 3G) or b-galacto-
sidase inPax3nlacZ/+embryos (Figure 3I). In the presence of Foxc2,
Pax3- and Pax7-expressing cells are not found in the wall of the
dorsal aorta where smooth muscle actin-positive cells are
present. A group of adjacent labeled cells shown in the Foxc2+/
embryo (Figure 3J, arrowhead) corresponds to a sympathetic
ganglion (Esner et al., 2006). This neural crest derivative is lost
in the Pax3nlacZ/nlacZ mutant, which provides a control for the
Foxc2/ vascular phenotype (Figure S4). In the absence of
Foxc2, the aorta forms, but the smooth muscle layer is affected
(Figure 3K).Pax3nlacZ/+-expressing cells arenow found in the posi-
tion of mural cells (Figure 3K). In these cells, smooth muscle actin
is no longer expressed, indicating that they have not acquired
a vascular fate. Transcript levels, estimated by qPCR (Figure 3L),
show a marked reduction for the endothelial marker Ang2 in
Foxc2/ embryos. In contrast, in Pax3 mutants, smooth muscle
and endothelial markers are more highly transcribed. These
observations suggest that the balance between Pax3 and
Foxc2 affects the fate of multipotent cells in the dermomyotome.
In order to investigate this further, we interfered with Pax3 and
Foxc2 levels in explant experiments. Noncanonical WNT
signaling from the dorsal ectoderm promotes Pax3 myogenic
activity in the underlying somites, as illustrated by inhibition ofDevelopmeprotein kinase-C (PKC), which is an intermediate in this pathway
(Brunelli et al., 2007). Inhibition of PKC in somite explants led to a
reduction in skeletal muscle and an increase in vascular smooth
muscle cells (Figures 4B and 4C). The balance of Pax3/7:Foxc2
expression was shifted in favor of the latter (Figure 4D). The
effect of the PKC inhibitor had been documented at the level of
transcriptional activity for Pax3 (Brunelli et al., 2007); however,
the more sensitive qPCR analysis used here shows downregula-
tion of transcripts as well, when PKC activity is inhibited. This
situation is reversed by a Foxc2-siRNA lentivirus that shifts the
balance back in favor ofPax3/7 (Figure 4H), with a corresponding
relative increase in skeletal versus vascular smooth muscle
derivatives (Figures 4F and 4G). This experiment thereforental Cell 17, 892–899, December 15, 2009 ª2009 Elsevier Inc. 895
Figure 4. Effects on Cell Fate after Manipulation of Pax3/7 and Foxc2 in Somite Explants
(A–H) Explants from presomitic mesoderm and the first three somites of E9.5 embryos were treated with an inhibitor (BIS) of protein kinase C (PKC) (A–D) or
infected with a lentivirus expressing Foxc2-siRNA (E–H). (A, B, E, F) Immunofluorescence using antibodies specific for skeletal muscle myosin (MHC, green)
and a-smooth muscle actin (a-SMA, red). Labeled cells were counted per field in control and treated explants and results standardized as 1 for the controls
(C and G). A minimum of ten fields were analyzed per experiment, with a minimum of six independent explants. Quantification of Foxc2, Pax3, and Pax7 mRNAs
relative to Gapdh transcripts, with the level in the control cultures taken as 1, for BIS in (D) and Foxc2-siRNA in (H) (n, number of plates [see Experimental Proce-
dures], n = 9 for BIS, n = 5 for Foxc2-siRNA). Scale bar, 50 mm in (A), (B), (C), (F). Histograms for qPCR (D and H) represent mean fold change of a minimum of three
biological samples analyzed in duplicate for each experiment; error bars, SEM; *p < 0.05; **p < 0.005, ***p < 0.0005. Scale bar, 50 mm in (A) and (E).
(I) An immature epithelial somite showing Pax3 and Foxc2 coexpression. At this and earlier stages, the main contribution of cells expressing Foxc2 (dashed arrow)
is to the endothelial wall of the aorta.
(J) A more mature somite in which the epithelial structure is retained in the dorsal dermomyotome, whereas this is lost ventrally in the mesenchymal sclerotome
(data not shown). Skeletal muscle of the myotome, which underlies the dermomyotome, has begun to form as a result of delamination of cells from this epithelium,
shown by black arrows for the central part and the hypaxial domain. Pax3 is expressed throughout the dermomyotome, whereas Pax7 expression is now detect-
able mainly in the central domain. Foxc2 expression is highest in the hypaxial domain. Pax3 (and Pax7) expression is maintained in myogenic progenitor cells that
will form the skeletal muscle of the myotome, whereas Foxc2 expression is maintained in cells that migrate to the dorsal aorta where, by this stage, they mainly
contribute to smooth muscle (Esner et al., 2006). The color code applies to regions where expression of the genes is relatively high (detectable by in situ hybrid-
ization and qPCR).
(K) Schema representing the reciprocal repression between Pax3 and Foxc2 and the consequences of perturbing it. Candidate signaling molecules for reducing
Pax3 inhibition of Foxc2 are noncanonical WNT acting through PKC. Notch signaling has been shown to promote the vascular cell fate in multipotent cells of the
chick dermomyotome (Ben-Yair and Kalcheim 2008).
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in cell fate choices in the dorsal somite.
DISCUSSION
Our identification of Foxc2 as a gene that depends on Pax3 leads
us to propose a mechanism operating in the multipotent cells of
the dermomyotome. First, genetic analyses reveal a reciprocal
negative regulation between Pax3/7 and Foxc2, which functions
in vivo, such that aspects of the Pax3 mutant phenotype can be
rescued by removal of Foxc2. Second, we show that perturba-
tion of the equilibrium between Pax3/7 and Foxc2 affects
myogenic versus vascular cell fates.
Foxc2 and Pax3 are regulated genetically by mutual repres-
sion. Since Pax3 acts mainly as a transcriptional activator in
the myogenic context (Relaix et al., 2003), this effect is probably
indirect, functioning through a Pax3-activated repressor. A can-
didate repressor is the class II histone deacetylase Hdac5. This
gene was a positively regulated target of Pax3 in our screen,
and Foxc2 expression is transitorily downregulated in Hdac5
mutants (unpublished data). However, these mutants have no
evident myogenic or vascular phenotype, suggesting possible
functional overlap with other class II Hdac genes. Foxc2, on
the other hand, potentially acts as a repressor in conjunction
with Groucho (Kume et al., 2001). A hypaxial regulatory element
has been described for the Pax3 gene (Brown et al., 2005), but it
does not have a complete Foxc2 binding site, as defined for
other genes (Yamagishi et al., 2003; De Val et al., 2008; Norrmen
et al., 2009). Further exploration of this regulation awaits identi-
fication of Foxc2 regulatory sequences for the dorsal somite
and investigation of Pax3 regulation in this domain.
When Pax3 function is compromised, removal of Foxc2 partially
rescues the Pax3 null phenotype. In particular, somites of Pax3/
Foxc2 double mutants are better organized and regain an epithe-
lial structure in the hypaxial dermomyotome, which is lost in the
absence of Pax3. This rescue is potentially due to Pax7 upregula-
tion, seen in the Foxc2 mutant, since Pax7 can compensate for
Pax3 loss-of-function phenotypes in the trunk (Relaix et al.,
2004). Foxc2 upregulation in Pax3 null embryos may contribute
to the loss of the hypaxial somite, since overexpression of
Foxc2 in metastatic cell lines promotes an epithelial-mesen-
chymal transition (EMT) and induces cell death (Mani et al.,
2007). In contrast, Pax3 overexpression incell lines leads to induc-
tion of a mesenchymal-epithelial transition, resulting in the forma-
tion of an epithelium (Wiggan et al., 2002). In the context of the
epithelial dermomyotome, upregulation of Foxc2 may result in
EMT and cell death, whereas Pax3 will promote epithelial integrity.
Effects on cell fate by manipulation of Foxc2 in both genetic
and explant experiments are partial, and this may reflect a role
for the related transcription factor, Foxc1, which is expressed,
like Foxc2, in the developing somite and shows functional over-
lap with Foxc2 (Kume et al., 2001). Both factors have similar DNA
binding sites (De Val et al., 2008). Although it did not emerge as
an evident target under the conditions of our screen, Foxc1
expression is increased in the somites of Pax3 mutants
(Figure S5). In Foxc1/Foxc2 double mutants, somitogenesis is
compromised; however, in single and compound mutants in
which somites form, the sclerotome is affected, leading to verte-
bral column defects (Winnier et al., 1997; Kume et al., 2001). InDevelopmethe sclerotome, where cells are committed to form cartilage/
bone and both Foxc1 and Foxc2 are present, Pax3 is no longer
expressed. Low levels of Foxc2 expression, on the other hand,
are retained in the dermomyotome where multipotent cells
continue to be present, and it is these cells that respond to
changes in the Pax3:Foxc2 ratio. Expression of Pax3 and
Foxc2 in the epithelial somite and in the dermomyotome of
mature somites, where Pax7 is also present, is illustrated in Fig-
ures 4I–4K, together with expression in myogenic and vascular
derivatives. We would speculate that the Pax3/7:Foxc2 repres-
sion loop plays a role in maintaining multipotent cells poised
between alternative cell fates. We show that perturbing the
Pax3:Foxc2 equilibrium (Figure 4K) by manipulating external
signals, such as noncanonical PKC-dependent Wnt signaling
that affects Pax3 activity (Brunelli et al., 2007), influences the
choice of myogenic versus other cell fates in the dermomyo-
tome. Other signaling pathways may also affect this equilibrium.
It is interesting in this context that Foxc2 is implicated in BMP
(Rice et al., 2003) and Notch signaling (Kume et al., 2001; Seo
et al., 2006; Hayashi and Kume 2008), both shown to be involved
in vascular cell fate choices in the dermomyotome of the chick
embryo (Ben-Yair and Kalcheim 2008). The choice between
smooth muscle and endothelial cell fates appears to involve
another level of regulation.
There is increasing evidence for the importance of negative
reciprocal regulation operating at the transcriptional level in con-
trolling cell fate decisions. This is exemplified by the double
negative gates that regulate cell lineage assignment during early
stages of development in the sea urchin and Drosophila embryo
(Davidson and Levine 2008). In the context of hematopoietic
stem cells, Gata1/Pu1 genes repress each other to influence
cell fate choices, and a mathematical model has been developed
that involves three stable states (Pu1high, Gata1high and Gata1+/
Pu1+) attained by additional autoregulation of the genes con-
cerned (Huang et al., 2007). In this paradigm, the intermediate
state, in which both genes are coexpressed, is particularly
important in maintaining multipotency. In the case of Pax3/
7:Foxc2, there is some evidence for Pax3 regulation of Pax7
(data not shown), but not of Pax3 autoregulation. Foxc2 autore-
gulation remains to be investigated.
The study reported here demonstrates the importance of
Pax3:Foxc2 reciprocal repression in modulating cell fate choices
in multipotent progenitors during vertebrate development. It also
provides a functional framework in which to investigate how
multipotency may be maintained.
EXPERIMENTAL PROCEDURES
Strains
Mouse lines are listed in Supplemental Data.
Dissection and Embryo Preparation
Embryos were collected after natural overnight mating and dated, taking
embryonic day (E) 0.5 as the day after the appearance of the vaginal plug.
Briefly, embryos were fixed in 4% paraformaldehyde at 4C overnight for
in situ hybridization, 2 hr for immunodetection, and 15 min for X-Gal staining.
In Situ Hybridization
Whole-mount in situ hybridizations with digoxigenin-labeled probes were per-
formed as described in Tajbakhsh et al., 1997. The c-met and Lbx1 probes
were a gift from C. Birchmeier (Berlin, Germany). In situ hybridization forntal Cell 17, 892–899, December 15, 2009 ª2009 Elsevier Inc. 897
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Pax3 and Foxc2 Genetic Interactions in the SomitePax7 and MyoD were carried out as described in Relaix et al., 2004. Foxc2 and
Foxc1 probes were synthesized using the image clones 30244569 and
5720391, respectively (Open Biosystems), and linearized by SphI and KpnI
enzymes, respectively. When needed, the whole-mount stained embryos
were embedded into gelatin-sucrose, frozen, and sectioned as described in
Lagha et al., 2008.
Reverse Transcription
RNA was extracted from embryonic material (interlimb somites or cultured
explants) and reverse transcribed using SuperScript II kit (Invitrogen).
Real-Time PCR
All PCR reactions were carried out in duplicate (triplicate for the standard
curves) using the Power Sybergreen Mix (Applied Biosystems) and a 7500
thermal cycler (Applied). All qPCR results are expressed as relative ratios of
the target cDNA to Gapdh transcripts normalized to that ratio in the reference
condition, which always corresponds to wild-type embryos or control experi-
ments for the explant assays. Since the quantifications in wild-type
and heterozygote embryos were equivalent, we pooled them in the control
category.
Primer sequences are listed in Supplemental Data.
Single Cell Analysis
Pax3GFP/+ embryos at E10.5 were dissected, to obtain immature caudal
somites and more mature interlimb somites, under a fluorescent microscope.
The neural tube and dorsal root ganglia were removed and in the case of the
interlimb somites, the epaxial region was also removed. The dissected somitic
material was dissociated using a 2 ml syringe and then filtered. GFP-positive
cells were isolated by flow cytometry (using the robotic arm of a MoFlo cell
sorter [Beckman Coulter]) and each single cell collected in a PCR tube contain-
ing 5 ml PBS 0.1%. Primers were first validated in a 10 cell assay and then
single cell PCR was carried out as described in Peixoto et al., 2004. Amplicons
obtained by qPCR were purified and sequenced to verify specificity. Primer
sequences are listed in Supplemental Data.
Screen
The complete listing of Pax3 putative target genes identified by a transcriptome
analysis on GFP-positive cells purified from forelimb buds and from somites of
Pax3PAX3-FKHR/GFP and Pax3GFP/+ embryos will be detailed in another article
(unpublished data).
Explant Culture
Presomitic mesoderm, followed by the first three somites, were dissected from
E9.5 embryos in PBS. The neural tube and dorsal ectoderm were removed
using a needle and somites cultured in DMEM/F12 with 20% fetal calf serum
as indicated in Brunelli et al., 2007. A minimum of three explants were cultured
per plate, with nine (BIS) or five (Foxc2-siRNA) plates per experiment. Three
hours after plating, the Bisindolylmaleimide I (BIS) inhibitor (Calbiochem)
was added to the culture at a concentration of 500 nM, diluted in DMSO,
and DMSO was added to the control plates. The inhibitor was added every
24 hr. The Foxc2-siRNA plasmid pSP-108 (U6P2) was kindly provided by
Dr. S. Mani (Houston, TX, USA) (Mani et al., 2007). The Foxc2-siRNA was
subcloned using BamHI/SalI into the lentivector RR.ppt.hPGK.GFP, without
GFP (Borello et al., 2006). The efficiency of the Foxc2-siRNA lentivirus was vali-
dated on cultured mesoangioblasts (data not shown). A control shRNA oligo,
which does not match any known mouse coding cDNA, was used as control.
The lentiviral vector was produced as described previously (Borello et al.,
2006). After 6 hr culture, the explants were infected with an MOI of 2.5, diluted
in the culture medium; this was changed to normal medium the following day.
All the explants were cultured for a total of 3 days.
Immunohistochemistry
Fluorescent coimmunohistochemistry on sections was carried out as
described previously (Lagha et al., 2008). Immunofluorescence on cultured
explants was carried out as described in Brunelli et al., 2007. Antibodies
used in this study are listed in Supplemental Data. Images were acquired
with Apotome Zeiss and Axiovision 4.6 software at the Pasteur imaging center
(Imagopole, Institut Pasteur). This system provides an optical slice view recon-898 Developmental Cell 17, 892–899, December 15, 2009 ª2009 Elsstructed from fluorescent samples, using a series of ‘‘grid projection’’ acquisi-
tions. Quantification of apoptosis and proliferation after immunostaining is
detailed in Supplemental Data.
Statistical Analysis
All qPCR data have been analyzed using the Mann-Whitney statistical test, as
recommended (Schefe et al., 2006). When the number of samples was higher
than 10, a Student’s t test has been used.
SUPPLEMENTAL DATA
Supplemental data include Supplemental Experimental Procedures and five
figures and can be found online with this article at http://www.cell.com/
developmental-cell/supplemental/S1534-5807(09)00444-4.
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